Study cohort
In total, 334 of >2000 individuals contacting specialized
allergy centers because a self- and-or clinically suspected (Fig.1)
immediate-type SARS-CoV-2 vaccine hypersensitivity were investigated
(Fig. 2). The median age of this cohort was 49 years (19-91), and
291/334 were female (87.1%). Medical history data were available for
151/334 patients. The history of the patients included anaphylaxis in
most cases to previous vaccination or drugs known or suspected to
contain PEG or PS80. Few patients reported on immediate reactions after
the use of cosmetics, were sensitized to multiple compounds or showed
systemic reactions to contrast media (Table 1).